Soledad M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Nivolumab, Ipilimumab, and Platinum-Based Chemotherapy in Stage IV Non-Small Cell Lung Cancer with Brain Metastases
- Phase III Trial of Sacituzumab Govitecan and Zimberelimab in Resected Non-Small Cell Lung Cancer Lacking Pathological Complete Response
- Evaluation of BNT327 Combined with Chemotherapy and Investigational Agents in First-Line Treatment of Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 16 of 159 partner sites.
Specializations
Advanced Lung Cancer Treatment
The investigator specializes in treating non-small cell lung cancer (NSCLC) with particular expertise in addressing various genetic mutations and molecular subtypes, including RET fusion-positive and KRAS G12C mutations.
- Targeted Therapy Applications
- Genetic Mutation Analysis
- Advanced Stage Treatment Protocols
Their work encompasses both early-stage and metastatic disease management.
Brain Metastasis Management
Demonstrates significant expertise in treating lung cancer with brain metastases, focusing on innovative therapeutic approaches including immunotherapy combinations and targeted treatments for ROS1-positive NSCLC.
- Intracranial Response Assessment
- Combined Modality Treatment
- Targeted Brain Metastasis Therapy
Specializes in monitoring intracranial treatment responses and clinical outcomes.
Innovative Treatment Combinations
Explores novel therapeutic combinations including chemotherapy with immunotherapy and targeted agents. The investigator's work includes evaluation of treatment sequencing strategies and adjuvant therapy approaches.
- Combination Therapy Development
- Treatment Response Assessment
- Disease-Free Survival Optimization
Focuses on improving survival outcomes through innovative treatment combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.